FLNA
Filana Therapeutics, Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Neutral
-2/100
Last price
0.87
▲ 0.01 (0.59%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
0.87
Day high
0.90
Day low
0.83
Volume
671.08K
Market cap
$42.26M
P/E (TTM)
—
52W range
0.67 – 4.98
Trailing performance
Returnvs SPY
1W
-5.43%
-7.4%
1M
+6.10%
+4.9%
3M
-26.27%
-30.8%
6M
-47.90%
-66.1%
YTD
-56.06%
-70.3%
1Y
-76.03%
-92.5%
3Y
-94.77%
-177.0%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on FLNA open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
990.31K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 30, 26 | BARRY RICHARD J Chief Executive Officer |
BUY | 306.81K | $278.13K | Indirect |
| Sep 28, 26 | BARRY RICHARD J Chief Executive Officer |
BUY | 93.09K | $78.20K | Indirect |
| Nov 24, 25 | ANDERSON ROBERT EUGENE JR Director |
BUY | 8.60K | $24.94K | Direct |
| Nov 20, 25 | BARRY RICHARD J Chief Executive Officer |
BUY | 150.00K | $414.00K | Indirect |
| Nov 19, 25 | BARRY RICHARD J Chief Executive Officer |
BUY | 73.39K | $201.81K | Indirect |
| Sep 30, 25 | COOK ROBERT CHRISTOPHER Chief Operating Officer |
BUY | 13.72K | $39.94K | Direct |
| Sep 22, 25 | BARRY RICHARD J Chief Executive Officer |
BUY | 7.17K | $16.35K | Indirect |
| Sep 19, 25 | BARRY RICHARD J Chief Executive Officer |
BUY | 237.94K | $534.74K | Indirect |
| Nov 29, 24 | SCHOEN ERIC J. Chief Financial Officer |
CONVERSION | 50.00K | $59.00K | Direct |
| Nov 29, 24 | SCHOEN ERIC J. Chief Financial Officer |
SELL | 61.80K | $238.47K | |
| Nov 29, 24 | KUPIEC JAMES WILLIAM Officer |
SELL | 4.00K | $15.48K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ANDERSON ROBERT EUGENE JR |
Director | 8.60K | Purchase |
BARRY RICHARD J |
Chief Executive Officer | — | Purchase |
COOK ROBERT CHRISTOPHER |
Chief Operating Officer | 13.72K | Purchase |
KUPIEC JAMES WILLIAM |
Officer | 0 | Sale |
SCHOEN ERIC J. |
Chief Financial Officer | 11.50K | Conversion of Exercise of derivative security |
Fundamentals
Market cap$42.26M
Enterprise value$-40.42M
Revenue (TTM)—
Gross profit$-15.65M
EBITDA$-12.69M
Net income$-42.28M
EPS (TTM)$-0.87
Free cash flow$3.98M
Total cash$82.68M
Total debt$0
Book value / share$1.32
Shares outstanding48.31M
Float46.92M
Short % of float13.14%
Dividend yield0.00%
Beta (5Y)-0.66
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio1.62
Price / sales—
Price / book0.66
EV / revenue—
EV / EBITDA3.19
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-55.78%
Return on assets-7.14%
Debt / equity—
Current ratio2.09
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $26.59M | $69.64M | $89.42M | $68.03M | -61.8% |
| Selling, general & admin | $68.80M | $71.81M | $16.53M | $11.99M | -4.2% |
| Total operating expense | $96.13M | $142.28M | $107.33M | $81.48M | -32.4% |
| Operating income | -$96.13M | -$142.28M | -$107.33M | -$81.48M | +32.4% |
| Net interest income | $4.62M | $8.51M | $7.83M | $2.78M | -45.7% |
| Pre-tax income | -$90.97M | -$24.34M | -$97.22M | -$76.25M | -273.7% |
| Net income | -$90.97M | -$24.34M | -$97.22M | -$76.25M | -273.7% |
| Net income to common | -$90.97M | -$24.34M | -$97.22M | -$76.25M | -273.7% |
| Basic EPS | -1.88 | -0.53 | -2.32 | -1.90 | -254.7% |
| Diluted EPS | -1.88 | -1.46 | -2.32 | -1.90 | -28.8% |
| EBIT | -$96.13M | -$142.28M | -$107.33M | -$81.48M | +32.4% |
| EBITDA | -$95.19M | -$141.15M | -$105.80M | -$80.18M | +32.6% |
| Basic shares | 48.30M | 46.33M | 41.93M | 40.20M | +4.2% |
| Diluted shares | 48.30M | 46.60M | 41.93M | 40.20M | +3.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $95.50M | $128.57M | $121.14M | $201.01M | — | -25.7% |
| Cash & short-term investments | $95.50M | $128.57M | $121.14M | $201.01M | — | -25.7% |
| Total current assets | $97.71M | $136.53M | $129.63M | $211.23M | — | -28.4% |
| Property, plant & equipment | $20.65M | $21.00M | $21.85M | $22.99M | — | -1.7% |
| Goodwill & intangibles | — | $37.00K | $176.00K | $622.00K | $1.07M | — |
| Total assets | $118.36M | $157.53M | $151.66M | $234.83M | — | -24.9% |
| Total current liabilities | $43.83M | $11.75M | $14.20M | $7.06M | — | +273.1% |
| Total debt | — | — | $0 | $139.00K | $236.00K | — |
| Total liabilities | $43.95M | $11.83M | $14.20M | $7.29M | — | +271.6% |
| Retained earnings | -$496.08M | -$405.11M | -$380.77M | -$283.55M | — | -22.5% |
| Shareholder equity | $74.40M | $145.70M | $137.47M | $227.54M | — | -48.9% |
| Working capital | $53.88M | $124.78M | $115.44M | $204.16M | — | -56.8% |
| Net tangible assets | $74.40M | $145.70M | $137.29M | $226.92M | — | -48.9% |
| Shares issued | 48.31M | 48.20M | 42.24M | 41.74M | — | +0.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$90.97M | -$24.34M | -$97.22M | -$76.25M | -273.7% |
| Depreciation & amortisation | $936.00K | $1.13M | $1.53M | $1.30M | -17.3% |
| Stock-based compensation | $19.58M | $16.29M | $4.59M | $2.07M | +20.2% |
| Change in working capital | $38.20M | -$1.83M | $9.08M | -$4.63M | +2,191.0% |
| Operating cash flow | -$32.25M | -$116.93M | -$82.03M | -$77.51M | +72.4% |
| Capital expenditure | -$581.00K | -$103.00K | -$414.00K | -$2.71M | -464.1% |
| Investing cash flow | -$581.00K | -$103.00K | -$414.00K | -$2.71M | -464.1% |
| Financing cash flow | -$239.00K | $124.47M | $2.56M | $47.80M | -100.2% |
| Free cash flow | -$32.83M | -$117.03M | -$82.44M | -$80.23M | +71.9% |
| End cash position | $95.50M | $128.57M | $121.14M | $201.01M | -25.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — |
| Research & development | $3.30M | $4.54M | $3.85M | $3.96M | $5.12M | -27.3% |
| Selling, general & admin | $6.09M | $6.62M | $9.70M | $7.91M | $40.28M | -8.1% |
| Total operating expense | $9.39M | $11.17M | $14.29M | $11.86M | $45.39M | -15.9% |
| Operating income | -$9.39M | -$11.17M | -$14.29M | -$11.86M | -$45.39M | +15.9% |
| Net interest income | $747.00K | $789.00K | $974.00K | $1.17M | $1.21M | -5.3% |
| Pre-tax income | -$8.60M | -$10.33M | -$12.54M | -$10.81M | -$44.22M | +16.7% |
| Net income | -$8.60M | -$10.33M | -$12.54M | -$10.81M | -$44.22M | +16.7% |
| Net income to common | -$8.60M | -$10.33M | -$12.54M | -$10.81M | -$44.22M | +16.7% |
| Basic EPS | -0.18 | -0.21 | -0.26 | -0.22 | -0.92 | +14.3% |
| Diluted EPS | -0.18 | -0.21 | -0.26 | -0.22 | -0.92 | +14.3% |
| EBIT | -$9.39M | -$11.17M | -$14.29M | -$11.86M | -$45.39M | +15.9% |
| EBITDA | -$9.15M | -$10.93M | -$13.92M | -$11.73M | -$45.17M | +16.3% |
| Basic shares | 48.31M | 48.31M | 48.31M | 48.31M | 48.31M | 0.0% |
| Diluted shares | 48.31M | 48.31M | 48.31M | 48.31M | 48.31M | 0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $82.68M | $86.57M | $95.50M | $106.08M | $112.38M | -4.5% |
| Cash & short-term investments | $82.68M | $86.57M | $95.50M | $106.08M | $112.38M | -4.5% |
| Total current assets | $83.72M | $87.96M | $97.71M | $108.91M | $114.82M | -4.8% |
| Property, plant & equipment | $20.18M | $20.40M | $20.65M | $20.82M | $20.56M | -1.1% |
| Total assets | $103.90M | $108.37M | $118.36M | $129.73M | $135.38M | -4.1% |
| Total current liabilities | $40.16M | $40.12M | $43.83M | $48.05M | $47.33M | +0.1% |
| Total liabilities | $40.29M | $40.23M | $43.95M | $48.16M | $47.41M | +0.2% |
| Retained earnings | -$515.02M | -$506.42M | -$496.08M | -$483.55M | -$472.74M | -1.7% |
| Shareholder equity | $63.61M | $68.14M | $74.40M | $81.57M | $87.97M | -6.7% |
| Working capital | $43.56M | $47.85M | $53.88M | $60.86M | $67.49M | -9.0% |
| Net tangible assets | $63.61M | $68.14M | $74.40M | $81.57M | $87.97M | -6.7% |
| Shares issued | 48.31M | 48.31M | 48.31M | 48.31M | 48.31M | 0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$8.60M | -$10.33M | -$12.54M | -$10.81M | -$44.22M | — | +16.7% |
| Depreciation & amortisation | $244.00K | $243.00K | $367.00K | $131.00K | $218.00K | — | +0.4% |
| Stock-based compensation | $4.07M | $4.07M | $5.37M | $4.40M | $4.58M | — | +0.0% |
| Change in working capital | $433.00K | -$2.86M | -$2.95M | $53.00K | $34.48M | — | +115.1% |
| Operating cash flow | -$3.85M | -$8.88M | -$9.75M | -$6.22M | -$4.95M | — | +56.6% |
| Capital expenditure | — | — | -$501.00K | — | — | — | — |
| Investing cash flow | — | — | -$501.00K | -$80.00K | $0 | $0 | — |
| Financing cash flow | -$16.00K | -$51.00K | -$329.00K | $0 | $0 | — | +68.6% |
| Free cash flow | -$3.88M | -$8.88M | -$10.25M | -$6.30M | -$4.95M | — | +56.3% |
| End cash position | $82.68M | $86.57M | $95.50M | $106.08M | $112.38M | — | -4.5% |
Options analytics
Put / call volume
0.33
Call-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
2.50
+185.7% from spot
ATM implied vol
50.0%
Nearest strike to spot
Skew (10% OTM)
-50.0%
Calls bid over puts
Call volume
6
Contracts, this expiry
Put volume
2
Contracts, this expiry
Heaviest call OI
2.50
0 contracts
Heaviest put OI
2.50
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.23 | -0.18 | +20.0% |
| Mar 2026 | -0.23 | -0.21 | +8.7% |
| Dec 2025 | -0.30 | -0.26 | +13.3% |
| Sep 2025 | -0.27 | -0.22 | +18.5% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.25 | 2 | $0 | 0.0% |
| Next quarter | -0.27 | 2 | $0 | 0.0% |
| Current year | -0.90 | 2 | $0 | 0.0% |
| Next year | -1.19 | 1 | $0 | 0.0% |
Analyst targets & ownership
Mean target$6.50
High target$8.00
Low target$5.00
Implied upside642.94%
Analyst count2
ConsensusSTRONG BUY
Strong buy / Buy1 / 1
Hold0
Sell / Strong sell0 / 0
Held by insiders2.05%
Held by institutions26.81%
Institutions holding109
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
0.87
+0.68% from price
SMA 20
0.82
+6.10% from price
SMA 50
0.88
-1.54% from price
SMA 100
1.06
-17.15% from price
SMA 200
1.49
-41.61% from price
EMA 12
0.87
+0.83% from price
EMA 26
0.86
+1.62% from price
EMA 50
0.91
-4.02% from price
RSI (14)
50.6
Neutral
MACD (12,26,9)
0.01
Hist 0.02
ATR (14)
0.13
15.11% of price
Realised vol 30D
132.6%
Annualised
Bollinger upper
1.01
20, 2σ
Bollinger lower
0.63
20, 2σ
50 / 200 cross
Death
0.88 vs 1.49
Trend bias
Below 200
-41.61%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
2.04
More volatile than market
Correlation to SPY
0.30
Largely independent
Realised vol 30D
132.6%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-85.3%
Peak to trough
Max drawdown 5Y
-99.3%
Peak to trough
ATR 14
0.13
15.11% of price
Beta (reported)
-0.66
5Y monthly, from filing
Short interest
Shares short
6.22M
Prior 6.31M
Change vs prior
-1.5%
Shorts covering
% of float
13.14%
Elevated
% of shares out
12.87%
Against total outstanding
Days to cover
23.7
Crowded exit
Float
46.92M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 6, 25 | LUCID CAPITAL MARKETS | INITIATED | — | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend dateDec 13, 2012
Next pay date—
Last split1:7
Split dateMay 10, 2017
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-22
Corporate Changes & Voting Matters
8-K · 2026-09-18
Corporate Changes & Voting Matters
8-K · 2026-07-29
Corporate Changes & Voting Matters
8-K · 2026-06-15
Periodic Financial Reports
10-Q · 2026-05-07
Annual Report to Shareholders
ARS · 2026-04-28
Corporate Changes & Voting Matters
8-K · 2026-03-12
Corporate Changes & Voting Matters
8-K · 2026-03-10
Headlines
Filana Therapeutics Insider Bought Shares Worth $278,132, According to a Recent SEC Filing
MT Newswires · 6d ago
BC-Most Active Stocks
Associated Press · 15d ago
Filana Therapeutics Announces FDA Lift of Clinical Hold on Simufilam, Enabling Phase 2a Study in TSC-Related Epilepsy
GlobeNewswire · 15d ago
Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update
GlobeNewswire · 70d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.